Triple Antithrombotic Therapy – Is It History or Should We Still Do It?

1. Capodanno D, Angiolillo DJ. Triple Antithrombotic Therapy at the Intercept Between Threats and Opportunities: Don’t Throw Out the Baby With the Bath Water. JACC Cardiovasc Interv. 2017;10:1086-1088.10.1016/j.jcin.2017.03.028Search in Google Scholar

2. Lamberts M, Olesen JB, Ruwald MH, et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation. 2012;126:1185-1193.10.1161/CIRCULATIONAHA.112.114967Search in Google Scholar

3. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019. pii: S0735-1097(19)30209-8.10.1161/CIR.0000000000000665Search in Google Scholar

4. Mantis C, Alexopoulos D. Antithrombotic treatment in atrial fibrillation patients undergoing PCI: Is dual therapy the winner? Thrombosis Research. 2019;176:133-139.Search in Google Scholar

5. Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J. 2018;39:213-254.10.1093/eurheartj/ehx419Search in Google Scholar

6. Senoo K, Lane D, Lip GY. Stroke and Bleeding Risk in Atrial Fibrillation. Korean Circ J. 2014;44:281.10.4070/kcj.2014.44.5.281Search in Google Scholar

7. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2015;50:e1-e88.Search in Google Scholar

8. Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381:1107-1115.10.1016/S0140-6736(12)62177-1Search in Google Scholar

9. Fiedler KA, Maeng M, Mehilli J, et al. Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial. J Am Coll Cardiol. 2015;65:1619-1629.10.1016/j.jacc.2015.02.05025908066Search in Google Scholar

10. Hammersley D, Signy M. Navigating the choice of oral anticoagulation therapy for atrial fibrillation in the NOAC era. Ther Adv Chronic Dis. 2017;8:165-176.10.1177/2040622317720106569214029201334Search in Google Scholar

11. Gibson CM, Mehran R, Bode C, et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med. 2016;375:2423-2434.10.1056/NEJMoa161159427959713Search in Google Scholar

12. Oldgren J, Steg PG, Hohnloser SH, et al. Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. Eur Heart J. 2019. pii: ehz059.10.1093/eurheartj/ehz059651483830793734Search in Google Scholar

13. Cannon CP, Bhatt DL, Oldgren J, et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med. 2017;377:1513-1524.10.1056/NEJMoa170845428844193Search in Google Scholar

14. Lopes RD, Vora AN, Liaw D, et al. An open-label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: rationale and design of the AUGUSTUS trial. Am Heart J. 2018;200:17-23.10.1016/j.ahj.2018.03.00129898844Search in Google Scholar

15. Lopes RD, Heizer G, Aronson R, et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med. 2019;380:1509-1524.10.1056/NEJMoa181708330883055Search in Google Scholar